top of page

ICAP Considerations for the Introduction of TLD in National Programs


This document is intended to support country programs to develop clinical guidance and implementation plans for the introduction of the fixed-dose combination (FDC) tablet of tenofovir

(TDF), lamivudine (3TC) and dolutegravir (DTG), (TLD). The primary audiences for this document are

HIV program managers, technical working group members, national HIV guideline committees and other stakeholders contributing to the development of national normative guidance for HIV treatment and planning for the rollout of TLD.



Bình luận


  • LinkedIn
  • Facebook
  • Twitter
  • Instagram
  • YouTube

383 Dorchester Avenue, Suite 400

Boston, MA 02127

The goal of the HIV New Product Introduction Toolkit is to stimulate conversations between government, partners, and communities on new product introduction. Please feel free to share any thoughts, questions, or additional resources for consideration by contacting us via email at HIVToolkit@clintonhealthaccess.org.

 

© 2022  Clinton Health Access Initiative - Global HIV Access Program

bottom of page